A randomized, double-masked, sham-controlled phase 3b/4 study of the efficacy, safety, and tolerability of intravitreal aflibercept monotherapy compared to aflibercept with adjunctive photodynamic therapy as indicated in subjects with polypoidal choroidal vasculopathy (PLANET)

Registry ID

EUCTR2013-004464-54

Source registry

EUCTR

Status

Completed

Phase

PHASE4

Sponsor

Bayer HealthCare AG

Start date

2014-05-13

Completion date

2017-07-07

Last update

2026-08-16

Conditions

• Polypoidal Choroidal Vasculopathy (PCV)

Summary

To collect data reflecting the efficacy and safety of aflibercept with and without photodynamic therapy rescue treatment in subjects diagnosed with the polypoidal choroidal vasculopathy subtype of wet age-related macular degeneration. To explore whether intravitreally administered aflibercept monotherapy is non-inferior to that of aflibercept plus photodynamic therapy (as indicated) based upon best-corrected visual acuity in subjects diagnosed with the polypoidal choroidal vasculopathy subtype of age-related macular degeneration.

Locations

• , , Germany
• , , Hungary

Related clinical trials

• Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy
• Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial

View on source registry